Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Neoplasms of the CNS

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 40 articles:
HTML format
Text format



Single Articles


    November 2017
  1. LORIOT Y, Pagliaro L, Flechon A, Mardiak J, et al
    Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Eur J Cancer. 2017;87:140-146.
    PubMed     Text format     Abstract available


  2. GEORGAKIS MK, Panagopoulou P, Papathoma P, Tragiannidis A, et al
    Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US.
    Eur J Cancer. 2017;86:46-58.
    PubMed     Text format     Abstract available


    September 2017
  3. GATTA G, Peris-Bonet R, Visser O, Stiller C, et al
    Geographical variability in survival of European children with central nervous system tumours.
    Eur J Cancer. 2017;82:137-148.
    PubMed     Text format     Abstract available


    August 2017
  4. PETRELLI F, Ghidini M, Lonati V, Tomasello G, et al
    The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Eur J Cancer. 2017;84:141-148.
    PubMed     Text format     Abstract available


  5. GAUDY-MARQUESTE C, Dussouil AS, Carron R, Troin L, et al
    Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Eur J Cancer. 2017;84:44-54.
    PubMed     Text format     Abstract available


    July 2017
  6. JIANG S, Eberhart CG, Zhang Y, Heo HY, et al
    Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas.
    Eur J Cancer. 2017;83:9-18.
    PubMed     Text format     Abstract available


  7. BLANK CU, Larkin J, Arance AM, Hauschild A, et al
    Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
    Eur J Cancer. 2017;79:176-184.
    PubMed     Text format     Abstract available


    June 2017
  8. GNEKOW AK, Walker DA, Kandels D, Picton S, et al
    A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report.
    Eur J Cancer. 2017;81:206-225.
    PubMed     Text format     Abstract available


  9. GANDHI L, Ignatius Ou SH, Shaw AT, Barlesi F, et al
    Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Eur J Cancer. 2017;82:27-33.
    PubMed     Text format     Abstract available


  10. KARREMANN M, Kramer N, Hoffmann M, Wiese M, et al
    Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
    Eur J Cancer. 2017;81:1-8.
    PubMed     Text format     Abstract available


    May 2017
  11. PISCIONE PJ, Bouffet E, Timmons B, Courneya KS, et al
    Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation.
    Eur J Cancer. 2017;80:63-72.
    PubMed     Text format     Abstract available


  12. STACCHIOTTI S, Saponara M, Frapolli R, Tortoreto M, et al
    Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    Eur J Cancer. 2017;76:84-92.
    PubMed     Text format     Abstract available


    April 2017
  13. EL-GALALY TC, Villa D, Michaelsen TY, Hutchings M, et al
    The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.
    Eur J Cancer. 2017;75:195-203.
    PubMed     Text format     Abstract available


  14. GEORGAKIS MK, Kalogirou EI, Liaskas A, Karalexi MA, et al
    Anthropometrics at birth and risk of a primary central nervous system tumour: A systematic review and meta-analysis.
    Eur J Cancer. 2017;75:117-131.
    PubMed     Text format     Abstract available


    March 2017
  15. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available


  16. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available


  17. DONIA M, Kimper-Karl ML, Hoyer KL, Bastholt L, et al
    The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.
    Eur J Cancer. 2017;74:89-95.
    PubMed     Text format     Abstract available


    February 2017
  18. CHOONG ES, Lo S, Drummond M, Fogarty GB, et al
    Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
    Eur J Cancer. 2017;75:169-178.
    PubMed     Text format     Abstract available


  19. JANSSENS GO, Gandola L, Bolle S, Mandeville H, et al
    Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
    Eur J Cancer. 2017;73:38-47.
    PubMed     Text format     Abstract available


  20. FOSSARD G, Ferlay C, Nicolas-Virelizier E, Rey P, et al
    Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Eur J Cancer. 2017;72:12-19.
    PubMed     Text format     Abstract available


  21. MANIAS KA, Gill SK, MacPherson L, Foster K, et al
    Magnetic resonance imaging based functional imaging in paediatric oncology.
    Eur J Cancer. 2017;72:251-265.
    PubMed     Text format     Abstract available


    January 2017
  22. URSU R, Carpentier A, Metellus P, Lubrano V, et al
    Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
    Eur J Cancer. 2017;73:30-37.
    PubMed     Text format     Abstract available


  23. TUCHEN M, Wilisch-Neumann A, Daniel EA, Baldauf L, et al
    Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Eur J Cancer. 2017;73:9-21.
    PubMed     Text format     Abstract available


  24. KHATUA S, Ramaswamy V, Bouffet E
    Current therapy and the evolving molecular landscape of paediatric ependymoma.
    Eur J Cancer. 2017;70:34-41.
    PubMed     Text format     Abstract available


    December 2016
  25. GENRE L, Roche H, Varela L, Kanoun D, et al
    External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
    Eur J Cancer. 2016;72:200-209.
    PubMed     Text format     Abstract available


    November 2016
  26. OULDAMER L, Bendifallah S, Chas M, Boivin L, et al
    Intrinsic and extrinsic flaws of the nomogram predicting bone-only metastasis in women with early breast cancer: An external validation study.
    Eur J Cancer. 2016;69:102-109.
    PubMed     Text format     Abstract available


    June 2016
  27. DE RUITER MA, Oosterlaan J, Schouten-van Meeteren AY, Maurice-Stam H, et al
    Neurofeedback ineffective in paediatric brain tumour survivors: Results of a double-blind randomised placebo-controlled trial.
    Eur J Cancer. 2016;64:62-73.
    PubMed     Text format     Abstract available


    April 2016
  28. JANG JE, Kim YR, Kim SJ, Cho H, et al
    A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
    Eur J Cancer. 2016;57:127-35.
    PubMed     Text format     Abstract available


    March 2016
  29. COHEN IJ
    Intraventricular methotrexate in addition to intravenous high dose methotrexate with folinic acid rescue: is it worth the bother?
    Eur J Cancer. 2016;56:179-80.
    PubMed     Text format    


  30. HYUN JW, Jeong IH, Joung A, Cho HJ, et al
    Leptomeningeal metastasis: Clinical experience of 519 cases.
    Eur J Cancer. 2016;56:107-14.
    PubMed     Text format     Abstract available


    January 2016
  31. POMPE RS, von Bueren AO, Mynarek M, von Hoff K, et al
    Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy'.
    Eur J Cancer. 2016 Jan 13. pii: S0959-8049(15)01041.
    PubMed     Text format    


    November 2015
  32. ROSSI M, Carioli G, Bonifazi M, Zambelli A, et al
    Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Eur J Cancer. 2015;52:41-49.
    PubMed     Text format     Abstract available


    September 2015
  33. VISSER O, Ardanaz E, Botta L, Sant M, et al
    Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study.
    Eur J Cancer. 2015 Sep 5. pii: S0959-8049(15)00712.
    PubMed     Text format     Abstract available


  34. POMPE RS, von Bueren AO, Mynarek M, von Hoff K, et al
    Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy.
    Eur J Cancer. 2015 Sep 4. pii: S0959-8049(15)00799.
    PubMed     Text format     Abstract available


    August 2015
  35. HENDRIKS LE, Derks JL, Postmus PE, Damhuis RA, et al
    Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study.
    Eur J Cancer. 2015 Aug 28. pii: S0959-8049(15)00798.
    PubMed     Text format     Abstract available


  36. HO VK, Gijtenbeek JM, Brandsma D, Beerepoot LV, et al
    Survival of breast cancer patients with synchronous or metachronous central nervous system metastases.
    Eur J Cancer. 2015 Aug 12. pii: S0959-8049(15)00746.
    PubMed     Text format     Abstract available


  37. VON BUEREN AO, Friedrich C, von Hoff K, Kwiecien R, et al
    Metastatic medulloblastoma in adults: Outcome of patients treated according to the HIT2000 protocol.
    Eur J Cancer. 2015 Aug 5. pii: S0959-8049(15)00650.
    PubMed     Text format     Abstract available


    July 2015
  38. PREUSSER M, Berghoff AS, Koller R, Zielinski CC, et al
    Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
    Eur J Cancer. 2015 Jul 8. pii: S0959-8049(15)00622.
    PubMed     Text format     Abstract available


  39. PAPATHOMA P, Thomopoulos TP, Karalexi MA, Ryzhov A, et al
    Childhood central nervous system tumours: Incidence and time trends in 13 Southern and Eastern European cancer registries.
    Eur J Cancer. 2015;51:1444-55.
    PubMed     Text format     Abstract available


    May 2015
  40. DURNO CA, Sherman PM, Aronson M, Malkin D, et al
    Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome.
    Eur J Cancer. 2015;51:977-83.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: